A PHASE 1/2 OPEN LABEL EXTENSION STUDY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA

• R. Marchi,
• L. Duarte,
• S. P,
• R. D,
• A. Ke,
• B. Hl,
• S. E,
• H. P,
• B. M,
• E. Al

Affiliations

R. Marchi

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil

L. Duarte

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil

S. P

King's College Hospital, London, United Kingdom

R. D

King's College Hospital, London, United Kingdom

A. Ke

University of Texas Medical Branch, Galveston, United States

B. Hl

Wake Forest University NC Baptist Medical Center, Winston-Salem, United States

S. E

Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

H. P

Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

B. M

Icahn School of Medicine at Mt. Sinai, New York, United States

E. Al

Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil